Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Eric J ShermanLara A DunnAlan L HoShrujal S BaxiRonald A GhosseinMatthew G FurySofia HaqueCami S SimaGrace CullenJames A FaginDavid G Pfister

Published in: Cancer (2017)

Sorafenib and temsirolimus appear to be an active combination in patients with radioactive iodine-refractory thyroid carcinoma, especially in patients who received no prior treatment compared with historic data from single-agent sorafenib. Activity is also observed in patients who previously received sorafenib. This regimen warrants further investigation. Cancer 2017;123:4114-4121. © 2017 American Cancer Society.

Keyphrases

papillary thyroid
randomized controlled trial
open label
big data
dual energy
replacement therapy